Alveolar rhabdomyosarcoma: Morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options

Oncotarget

Volumn 7, Issue 29, 2016, Pages 46263-46272

  Brown, Robert E ^a   Buryanek, Jamie ^a   Katz, Amanda M ^b   Paz, Keren ^b   Wolff, Johannes E ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Champions Oncology   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alveolar rhabdomyosarcoma; Morphoproteomics; PAX3 FKHR subtype; Targeted therapy; Xenograft testing

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; ENTINOSTAT; IRINOTECAN; METFORMIN; NAVELBINE; PEMETREXED; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; VALPROIC ACID; VORINOSTAT; ONCOPROTEIN; PAX3-FKHR FUSION PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER MORPHOLOGY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHEMORADIOTHERAPY; CHILD; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HAND DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; MORPHOPROTEOMICS; ONCOLOGICAL PROCEDURE; PERSONALIZED TUMOR GRAFT TESTING; PROTEOMICS; RECURRENCE RISK; RETROPERITONEAL CANCER; RHABDOMYOSARCOMA; RISK REDUCTION; SCHOOL CHILD; TESTIS CANCER; TREATMENT RESPONSE; TUMOR BIOPSY; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HAND; MOUSE; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SOFT TISSUE TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CHILD; HAND; HUMANS; MALE; MICE; ONCOGENE PROTEINS, FUSION; PRECISION MEDICINE; PROTEOMICS; RHABDOMYOSARCOMA, ALVEOLAR; SOFT TISSUE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979955515     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10089     Document Type: Article

References (49)

1. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002; 20:2672-2679.
2. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010: 70:6497-6508.
3. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res. 2001; 11:289-297.
4. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998; 58:3542-3546.
5. Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer BW, Buckingham M. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligandindependent activation of Met signaling in vivo. Genes Dev. 2003; 17:2950-2965.
6. Zeng FY, Dong H, Cui J, Liu L, Chen T. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells. Biochem Biophys Res Commun. 2010: 391:1049-1055.
7. Wang S, Guo L, Dong L, Guo L, Li S, Zhang J, Sun M. TGF-beta1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation. Cancer Sci. 2010; 101:1108-1116.
8. Sun MM, Li JF, Guo HT, Xiao HT, Dong L, Wang F, Huang FB, Cao D, Qin T, Yin XH, Li JM, Wang SL. TGF-β1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014; 33:2075-2086.
9. Gerber AN, Wilson CW, Li YJ, Chuang PT. The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation. Oncogene. 2007; 26:1122-1136.
10. Dennler S, Andre J, Alexaki I, Li A, Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F, Mauviel A. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 2007; 67:6981-6986.
11. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008; 14:369-381.
12. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 2004; 18:2627-2638.
13. Ciarapica R, Miele L, Giordano A, Locatelli F, Rota R. Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med. 2011; 9:63.
14. Walters ZS, Villarejo-Balcells B, Olmos D Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene. 2014: 33:1148-1157.
15. Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene. 2014; 33:4173-4184.
16. Kaneko S, Bonasio R, Saldana-Meyer R, Yoskida T, Son J, Nishino K, Umezawa A, Reinberg D. Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Mol Cell. 2014; 53:290-300.
17. Rota R, Ciarapica R, Giordano A, Miele L, Locatelli F. MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer. 2011; 10:120.
18. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Review in Proteomics. 2005; 2: 337-348.
19. Brown RE. Morphogenomics and morphoproteomics: A role for Anatomic Pathology in Personalized Medicine. Archives of Pathology and Laboratory Medicine. 2009; 133: 568-579.
20. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids. 2010; 38:223-228.
21. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet. 2008; 17:2934-2948.
22. Glidden EJ, Gray LG, Vemuru S, Li D, Harris TE, Mayo MW. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. J Biol Chem. 2012: 287:581-588.
23. Xu Y, Lai E, Liu J, Lin J, Yang C, Jia C, Li Y, Bai X, Li M. IKK interacts with rictor and regulates mTORC2. Cell Signal. 2013: 25:2239-2245.
24. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010; 123:271-279.
25. Calvanese V1, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N, López-Nieva P, Horrillo A, Hmadcha A, Soria B, Piazzolla D, Herranz D et al. Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A. 2010: 107:13736-13741.
26. Wang H, Liu H, Chen K, Xiao J, He K, Zhang J, Xiang G. SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep. 2012: 28:311-318.
27. Qu Y, Zhang J, Wu S, Li B, Liu S, Cheng J. SIRT1 promotes proliferation and inhibits apoptosis of human malignant glioma cell lines. Neurosci Lett. 2012: 525:168-172.
28. Puri PL, Iezzi S, Stiegler P, Chen TT, Schiltz RL, Muscat GE, Giordano A, Kedes L, Wang JY, Sartorelli V. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol Cell. 2001; 8:885-897.
29. Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, Wachtel M, Bode P, Nanni P, Blank B, Koscielniak E, Schäfer BW. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma. Cancer Res. 2015: 75:98-110.
30. Jothi M, Mal AK. Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma. Oncotarget. 2012: 3:1064-1065. doi: 10.18632/oncotarget.713.
31. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66:1500-1508.
32. Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, Cunningham AL, Gray L, Churchill M, Cameron PU, Dear AE, Lewin SR. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS. 2013; 27:2853-2862.
33. Abraham J, Nunez-Alvarez Y, Hettmer S, Carrió E, Chen HI, Nishijo K, Huang ET, Prajapati SI, Walker RL, Davis S, Rebeles J, Wiebush H, McCleish AT, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 2014; 28:1578-1591.
34. Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ. Lossof-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Lett. 2014; 354:336-347.
35. Christensen MD, Elmer JJ, Eaton S, Gonzalez-Malerva L, LaBaer J, Rege K. Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. J Control Release. 2015; 204:20-29.
36. Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neurooncol. 2012: 106:99-109.
37. Balasubramanian S, Chew YC, Eckert RL. Sulforaphane suppresses polycomb group protein level via a proteasomedependent mechanism in skin cancer cells. Mol Pharmacol. 2011; 80:870-878.
38. Bergantin E, Quarta C, Nanni C, Fanti S, Pession A, Cantelli-Forti G, Tonelli R, Hrelia P. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAILsensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. Cancer Biol Ther. 2014; 15:1219-1225.
39. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell. 2009; 36:61-74.
40. Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D. et al. Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer. 2006; 47:773-784.
41. Al-Tahan A, Sarkis O, Harajly M, Baghdadi OK, Zibara K, Boulos F, Dighe D, Kregel S, Bazarbachi A, El-Sabban M, Skapek SX, Saab R. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. Pediatr Blood Cancer. 2012: 58:877-884.
42. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer. 2012: 106:77-84.
43. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012: 5:355-364.
44. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle. 2009; 8:172-175.
45. Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA. Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle. 2009; 8:1633-1636.
46. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y. Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signalling pathway. Cardiovasc Res. 2010: 87:504-513.
47. Nakamura M, Ogo A, Yamura M, Yamaguchi Y, Nakashima H. Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. Anticancer Res. 2014; 34:1765-1769.
48. Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G, Wei J. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 2015; 36:204-214.
49. Sun H, McGuire MF, Zhang S, Brown RE. NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates. Ann Clin Lab Sci. 2015; 45:692-701.